|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||An 18 amino acid peptide from near the amino terminus of human Aven.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||5 µg/ml|
|Western Blot (WB)||1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Despite its predicted molecular weight, Aven often migrates at 55kDa in SDS-PAGE. A suggested positive control is Raji cell lysate.
PA5-20288 can be used with blocking peptide PEP-0406.
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. Aven is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that Aven functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that Aven impedes Apaf-1-mediated caspase activation. Higher levels of Aven mRNA are seen in patients with acute leukemia than in control patients, suggesting that Aven may be useful as a prognostic indicator in leukemia patients.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.